What does PHARMALAW do?

PHARMALAW is a legal practice in Tervuren. Private Limited, started on 14 August 2018, 1 establishment.

What is the address of PHARMALAW?

The registered office of PHARMALAW is located at Beukenlaan 7, 3080 Tervuren.

Is PHARMALAW still active?

Yes. According to the CBE (29 October 2026) PHARMALAW is active, legal situation “Normale toestand”, started on 14 August 2018.

Is PHARMALAW registered on Peppol?

Yes, PHARMALAW is registered on the Peppol network with ID 0208:0700871124.

What is the enterprise number of PHARMALAW?

The enterprise number of PHARMALAW is BE0700871124.

When was PHARMALAW founded?

PHARMALAW was founded on 14 August 2018.

Who are the directors of PHARMALAW?

According to the 2025 annual accounts, the directors of PHARMALAW are: Christian Matton.

Is PHARMALAW a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 14 August 2018; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMALAW make in 2025?

PHARMALAW posted a profit after taxes of € 177,801 in financial year 2025.

What is the revenue of PHARMALAW?

As a small company, PHARMALAW is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 257,446.

PHARMALAW (Private Limited) - Tervuren - BE0700871124

Dossier PHARMALAW, printed on 29 October 2026 from databakkes.be/en/0700871124/pharmalaw. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMALAW from Tervuren, company number BE0700871124, closed financial year 2025 with a result of € 177,801 after tax. For that financial year PHARMALAW recorded a gross margin of € 257,446 and equity of € 433,741. Compared with financial year 2024, the result moved from € 112,455 to € 177,801. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 17, 2026.

What it is worth Healthy

€ 433,741

▼ 29% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 177,801

▲ 58% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 449,594

▲ 29% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 358,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Vehicles and equipment

€ 1,081

▼ 41% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 11,324

▲ 3% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 92,844

▲ € 91,417 vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 175,035 Gross margin 2022: € 175,035 First fiscal year in the series	€ 173,235 Gross margin 2023: € 173,235 ▼ 1% vs 2022 (€ 175,035) Unfavourable step	€ 148,484 Gross margin 2024: € 148,484 ▼ 14% vs 2023 (€ 173,235) Unfavourable step	€ 257,446 Gross margin 2025: € 257,446 ▲ 73% vs 2024 (€ 148,484) Favourable step	▲ 73%
Profit after taxes	€ 122,100 Profit after taxes 2022: € 122,100 First fiscal year in the series	€ 130,294 Profit after taxes 2023: € 130,294 ▲ 7% vs 2022 (€ 122,100) Favourable step	€ 112,455 Profit after taxes 2024: € 112,455 ▼ 14% vs 2023 (€ 130,294) Unfavourable step	€ 177,801 Profit after taxes 2025: € 177,801 ▲ 58% vs 2024 (€ 112,455) Favourable step	▲ 58%
Equity	€ 479,051 Equity 2022: € 479,051 First fiscal year in the series	€ 609,345 Equity 2023: € 609,345 ▲ 27% vs 2022 (€ 479,051) Favourable step	€ 613,940 Equity 2024: € 613,940 ▲ 1% vs 2023 (€ 609,345) Favourable step	€ 433,741 Equity 2025: € 433,741 ▼ 29% vs 2024 (€ 613,940) Unfavourable step	▼ 29%
Total debts	€ 71,712 Total debts 2022: € 71,712 First fiscal year in the series	€ 41,357 Total debts 2023: € 41,357 ▼ 42% vs 2022 (€ 71,712) Favourable step	€ 79,589 Total debts 2024: € 79,589 ▲ 92% vs 2023 (€ 41,357) Unfavourable step	€ 225,168 Total debts 2025: € 225,168 ▲ 183% vs 2024 (€ 79,589) Unfavourable step	▲ 183%
Cash	€ 442,827 Cash 2022: € 442,827 First fiscal year in the series	€ 300,483 Cash 2023: € 300,483 ▼ 32% vs 2022 (€ 442,827) Unfavourable step	€ 349,215 Cash 2024: € 349,215 ▲ 16% vs 2023 (€ 300,483) Favourable step	€ 449,594 Cash 2025: € 449,594 ▲ 29% vs 2024 (€ 349,215) Favourable step	▲ 29%
Retained profit	€ 472,851 Retained profit 2022: € 472,851 First fiscal year in the series	€ 603,145 Retained profit 2023: € 603,145 ▲ 28% vs 2022 (€ 472,851) Favourable step	€ 607,740 Retained profit 2024: € 607,740 ▲ 1% vs 2023 (€ 603,145) Favourable step	€ 427,541 Retained profit 2025: € 427,541 ▼ 30% vs 2024 (€ 607,740) Unfavourable step	▼ 30%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 107,860 Dividend 2024: € 107,860 Unchanged (€ 0) Unchanged	€ 358,000 Dividend 2025: € 358,000 ▲ 232% vs 2024 (€ 107,860) Unchanged	▲ 232%
Balance sheet total	€ 550,763 Balance sheet total 2022: € 550,763 First fiscal year in the series	€ 650,702 Balance sheet total 2023: € 650,702 ▲ 18% vs 2022 (€ 550,763) Unchanged	€ 693,529 Balance sheet total 2024: € 693,529 ▲ 7% vs 2023 (€ 650,702) Unchanged	€ 658,909 Balance sheet total 2025: € 658,909 ▼ 5% vs 2024 (€ 693,529) Unchanged	▼ 5%

Key figures of PHARMALAW, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMALAW?

What happened at PHARMALAW in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 17, 2026 New annual accounts for financial year 2025: profit of € 177,801 (▲ 58% vs 2024). Source: NBB ↗
2023 Christian Matton became a director. NBB
Aug 14, 2018 New establishment in Tervuren. KBO
Aug 14, 2018 Start of the company according to the CBE. KBO

In short

From € 122,100 profit in 2022 to € 177,801 profit in 2025.

Paid € 229,946 in corporate taxes since 2022.

Best year ever: 2025, with € 177,801 profit.

Paid out € 465,860 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Christian Matton

PHARMALAW

MANAGEMENT ANCHORAGE

Behind PHARMALAW is Christian Matton. Christian Matton is also behind MANAGEMENT ANCHORAGE.

Directors

According to the 2025 annual accounts

Christian Matton

Director

Also active at: MANAGEMENT ANCHORAGE

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Beukenlaan 7

3080 Tervuren

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0700.871.124
VAT number: BE 0700.871.124
Registered office: Beukenlaan 7, 3080 Tervuren
Names & denominations: PHARMALAW
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 14 August 2018
Peppol: Active · Active since 2 Dec 2025
Activities · NACE: Overige rechtskundige dienstverlening

View on CBE Public ↗ Annual accounts (NBB) ↗